: iStockAnalyst.com Symbols Feed

The Week in Review: Major Investments

Sun, 08 Nov 2009 01:33:43 GMT

Novartis made a five-year, $1 billion China commitment, building up its Shanghai R&D center and marketing efforts; Novartis will also spend $250 million to expand its global technical center in Changshu, and pay $125 million to buy a 85% stake in vaccine maker Zhejiang Tianyuan; Roche opened a new $500 million biologics manufacturing facility in Singapore; Microbix and Hunan Biopharmaceutical Co. will construct a $200 million flu vaccine facility;[More...]

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Tue, 06 Oct 2009 21:44:54 GMT

Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the Company, including an update on the FDA status for M-Enoxaparin.[More...]

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Fri, 02 Oct 2009 16:55:00 GMT

On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP).[More...]

How To Find The Best Potential Profit Plays In The Resurgent M&A And IPO Markets

Tue, 29 Sep 2009 13:52:15 GMT

When Xerox Corp. (NYSE: XRX) yesterday (Monday) unveiled plans to pay $6.4 billion for outsourcing specialist Affiliated Computer Services Inc. (NYSE: ACS), it was just one of four major financing deals with an aggregate value of more than $14 billion announced on the day.[More...]

10 Health-Care Stocks To Consider Buying Now

Mon, 28 Sep 2009 13:38:54 GMT

Our Ultimate Stock-Pickers continue to load up on health-care stocks.[More...]

Get Paid To Trade With Dividends: NVS, MRK, KFT, JNJ, PG, CVX

Sun, 27 Sep 2009 18:39:50 GMT

According to Wharton finance professor Jeremy Seigel, one of the more respected minds in economics, 97% of stock market gains come from one thing and one thing only.[More...]

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Mon, 21 Sep 2009 03:49:21 GMT

Pressure BioSciences (NASDAQ: PBIO) is a life science research tools company that is commercializing and developing its innovative core technology platform known as pressure cycling technology (PCT). PCT uses cycles of hydrostatic (water-based) pressure between ambient and ultra-high levels (up to 45,000 PSI) at controlled temperatures to rapidly and repeatedly control interactions at the molecular level.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Swine Flu H1N1, What Makes This Flu Scary (SVA, GLID, GSK, NVS)

Wed, 16 Sep 2009 17:24:00 GMT

Swine Flu, officially known as N1H1 influenza , is having a far reaching effect on every one of us. The virus was first tracked in a small town in Mexico in May of 2009 and has spread to nearly every part of the world.[More...]

QLT Announces Third Quarter Results for 2009

Tue, 27 Oct 2009 11:48:00 GMT

QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM
VANCOUVER, Oct. 27 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the third quarter ended September 30, 2009.
For the third quarter and nine months ended September 30, 2009, QLT is reporting the results of our divested QLT USA business as one line item called Income from Discontinued Operations on our statements of operations.

[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 17:12:00 GMT

UPI NewsTrack TopNews[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 12:29:00 GMT

UPI NewsTrack TopNews[More...]

CDC: 16 million flu vaccine doses shipped

Sat, 24 Oct 2009 12:07:00 GMT

CDC: 16 million flu vaccine doses shipped[More...]

UPI NewsTrack Health and Science News

Tue, 15 Sep 2009 21:46:00 GMT

UPI NewsTrack Health and Science News[More...]

FDA approves four H1N1 vaccines

Tue, 15 Sep 2009 19:50:00 GMT

FDA approves four H1N1 vaccines[More...]

One-dose H1N1 vaccine may be on the way

Fri, 04 Sep 2009 04:22:00 GMT

One-dose H1N1 vaccine may be on the way[More...]

Canada studies asthma drug Xolair risks

Thu, 13 Aug 2009 16:32:00 GMT

Canada studies asthma drug Xolair risks[More...]

Alcon Profit Rises 2.6% in Second Quarter

Thu, 23 Jul 2009 06:08:00 GMT

Jul. 23--Leading eye-care company Alcon Laboratories said net earnings increased by 2.6 percent in the second quarter, driven in part by sales for cataract and glaucoma treatments and reduced expenses from cost-cutting.
The Fort Worth-based company (ticker: ACL) reported global sales of $1.68 billion for the three-month period ending in June, Alcon said in a statement released Wednesday after the markets closed.
That would have been an increase of 3.3 percent excluding foreign exchange fluctuations, a figure the company refers to as "organic sales growth."

[More...]

Scientists solve a drug shelf-life problem

Wed, 08 Jul 2009 20:33:00 GMT

Scientists solve a drug shelf-life problem[More...]

Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

Tue, 03 Nov 2009 04:47:00 GMT

Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009.
Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider.
I am pleased to be joining the Board of Fresenius Kabi Pharmaceuticals Holding and look forward to using my experience to expand APP's pipeline, while exploring new opportunities that will position it for future growth," said Dr. Hampl.

[More...]

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK

Tue, 27 Oct 2009 11:10:00 GMT

RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment.
Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.
We have recently begun in-depth analysis of the following equities & their respective sectors:

[More...]

Novus Energy Inc. grants performance warrants and options

Fri, 04 Sep 2009 17:03:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.

Wed, 26 Aug 2009 13:46:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones.
ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.

[More...]

Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes

Wed, 26 Aug 2009 11:50:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary.
The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.
The tender offer is being made pursuant to an Offer to Purchase, dated August 26, 2009, and related Letter of Transmittal, dated August 26, 2009, which set forth the terms and conditions and a more detailed description of the tender offer.

[More...]

Novus Energy Inc. announces third quarter 2009 results

Tue, 25 Aug 2009 21:57:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009

Tue, 25 Aug 2009 15:45:00 GMT

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis . PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.[More...]

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Thu, 06 Aug 2009 10:48:00 GMT

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), The Leading Provider of Real Estate to the Life Science Industry(R), announced today that its board of directors and corporate officers will ring The Closing Bell(R) at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering.
BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell(R).
"This is a great day for our team," said Mr. Gold.

[More...]

Standard & Poor's annonce des modifications a l'indice compose S&P/TSX de croissance

Tue, 04 Aug 2009 21:37:00 GMT

TORONTO, le 4 aout /CNW/ - Standard & Poor's apportera les modifications suivantes a l'indice compose S&P/TSX de croissance le mardi 4 aout 2009, apres la cloture des marches :[More...]

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

Thu, 30 Jul 2009 14:46:00 GMT

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter.
Net income for the three months ended June 30, 2009, was $30.0 million, compared with $57.1 million in the comparable 2008 period.
As detailed in the supplemental financial information below, adjusted net income for the three months ended June 30, 2009, was $85.9 million, compared with $72.7 million in the same period in 2008.

[More...]